As a consequence of reprogrammed myeloid and T cells, S100a4−/− glioma-bearing mice live significantly longer than B6 wild-type host mice, validating the potential of S100A4 as an immunotherapy target in GBM. This evidence concerns the gene S100A4 and glioma.